Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic was created in 2015 with co-founders Polaris Partners, T.A. Springer and Schrödinger, Inc., along with ShangPharma Investment Group. For more information, visit www.morphictx.com
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/30/16 | $51,500,000 | Series A |
AbbVie Biotech Ventures Omega Funds Pfizer Venture Investments Polaris Partners Schrodinger, Inc ShangPharma Investment Group SR One TA Springer | undisclosed |
| 09/26/18 | $80,000,000 | Series B |
EcoR1 Capital Invus Novo Holdings  Omega Funds | undisclosed |
